Rh+全血能否安全替代Rh-血制品?某医院低效价O型全血项目可持续性改进分析
按受血者Rh状态分层后Rh+者577例、Rh-者70例。结果显示,无论按所输制品Rh状态还是受血者Rh状态分组,溶血实验室指标、输血反应、并发症及生存率均无差异。结论认为,当Rh-全血不可用或供应短缺时,Rh+ LTO-WB似乎是Rh+和Rh-患者失血性休克复苏的安全替代选择,有助于创伤中心实施并维持LTO-WB项目。
要点
- 按受血者Rh状态分层(Rh+ 577例、Rh- 70例),无论接受Rh+还是Rh-制品,溶血实验室、输血反应、并发症及生存均无差异。
- 接受Rh+制品的患者更多为男性(81% vs 70%)、现场血压更低(中位99 vs 109)、GCS更低(中位7 vs 12),均p<0.05。
- Rh-受血者较Rh+受血者年龄更大(中位54 vs 39岁)、更多为女性(57% vs 26%)、更多为钝性创伤(92% vs 70%),均p<0.05。
- 结论支持在Rh-全血不可用或短缺时,Rh+ LTO-WB可作为Rh+和Rh-患者失血性休克复苏的安全替代,证据等级为治疗性Level III。
适用人群与场景
- 接受院前或急诊科输注未交叉配血、紧急释放低效价O型全血(LTO-WB)的连续创伤患者(研究期11/17-10/19)。
- 按所输制品分为Rh+制品组(448例)与Rh-制品组(189例);按受血者Rh状态分为Rh+患者(577例)与Rh-患者(70例)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 对需要紧急释放LTO-WB输注的创伤患者,在Rh-全血不可用或供应短缺时,可使用Rh+ LTO-WB作为替代(原文结论性推荐,未给出具体剂量方案)。
- 研究中监测了系列溶血实验室指标和输血反应,但原文未提及具体的监测频次或停药阈值。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的具体红旗征。
研究设计与关键结果
- Rh+制品组448例 vs Rh-制品组189例:血制品输注量、溶血实验室指标、输血反应、并发症及生存率均无差异。
- 接受Rh+制品者更多为男性(81% vs 70%)、现场血压更低(中位99 vs 109)、GCS更低(中位7 vs 12),均p<0.05。
- 按受血者Rh状态:Rh+患者577例、Rh-患者70例;Rh-患者年龄更大(中位54 vs 39岁)、更多女性(57% vs 26%)、更多钝性创伤(92% vs 70%),均p<0.05。
- 无论受血者Rh状态如何,接受Rh+或Rh-制品的患者在溶血实验室、输血反应、并发症及生存方面均无差异。
证据类型、等级与局限
- 证据类型:单中心回顾性分析(治疗性研究,证据等级Level III)。
- 局限:原文未明确列出局限性;设计本身为回顾性、单中心、样本中Rh-受血者仅70例。
对床旁实践的改变
- 当Rh-全血不可用或供应短缺时,创伤中心可考虑使用Rh+ LTO-WB对Rh+和Rh-患者进行失血性休克复苏,以改善LTO-WB项目的可持续性。
- 研究显示接受Rh+制品的患者病情更重(现场血压和GCS更低),但溶血实验室、输血反应、并发症及生存无差异,提示病情差异未导致安全性信号。
- Rh-受血者仅70例,解读Rh-患者使用Rh+制品的安全性时需注意样本量有限。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Low-titer group O whole blood (LTO-WB) has recently gained popularity in trauma centers for the acute resuscitation of hemorrhagic shock. However, limited supplies of Rh- product prevent implementation and strain sustainability at many trauma centers. We set out to identify whether Rh+ LTO-WB could be safely substituted for RH- product, regardless of patient's Rh status.
METHODS: Following Institutional Review Board approval, information on all trauma patients receiving prehospital or emergency department transfusion of uncrossed, emergency release LTO-WB (11/17-10/19) were evaluated. Patients were first divided into those who received Rh- versus Rh+ product, the assessed by Rh of the recipient. Serial hemolysis panels, transfusion reactions, and outcomes were compared.
RESULTS: Six hundred thirty-seven consecutive trauma patients received emergency release LTO-WB. Of these, 448 received Rh+ product, while 189 received Rh- LTO-WB. Patients receiving Rh+ product were more likely to be men (81 vs. 70%) and have lower field blood pressure (median 99 vs. 109) and GCS (median 7 vs. 12); all p < 0.05. There were no differences in blood product volume, hemolysis laboratories, transfusion reactions, complications, or survival. We then separated patients by Rh status (577 were Rh+, 70 were Rh-). Rh- patients were older (median age 54 vs. 39), more likely to be women (57 vs. 26%), and more likely to have sustained blunt trauma than their Rh+ counterparts (92 vs. 70%); all p < 0.05. There were no differences in hemolysis laboratories, transfusion reactions, complications, or survival between Rh+ and Rh- patients, regardless of Rh product received.
CONCLUSION: When Rh- whole blood is unavailable or in short supply, Rh+ LTO-WB appears to be a safe alternative for the resuscitation of hemorrhagic shock in both Rh+ and Rh- patients. Use of Rh+ product may help trauma centers incorporate LTO-WB into their hospital and improve sustainability of such programs.
LEVEL OF EVIDENCE: Therapeutic, Level III.
参考来源
- McCoy CC, Montgomery K, Cotton ME, et al. Can RH+ whole blood be safely used as an alternative to RH- product? An analysis of efforts to improve the sustainability of a hospital's low titer group O whole blood program. J Trauma Acute Care Surg. 2021. PMID: 34238860. doi:10.1097/TA.0000000000003342
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。